<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Pediatr</journal-id>
<journal-id journal-id-type="publisher-id">TP</journal-id>
<journal-title-group>
<journal-title>Translational Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="epub">2224-4344</issn>
<publisher>
<publisher-name>AME Publishing Company</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26835392</article-id>
<article-id pub-id-type="pmc">4728993</article-id>
<article-id pub-id-type="publisher-id">tp-04-04-304</article-id>
<article-id pub-id-type="doi">10.3978/j.issn.2224-4336.2015.10.07</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Rare Diseases Column (Review Article)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Phenylketonuria: a review of current and future treatments</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Al Hafid</surname>
<given-names>Naz</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Christodoulou</surname>
<given-names>John</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<aff><target id="aff1" target-type="aff"><sup>1</sup></target>Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, <country>Australia</country>; <target id="aff2" target-type="aff"><sup>2</sup></target>Genetic Metabolic Research Unit, Western Sydney Genetics Program, The Children’s Hospital at Westmead, Sydney, <country>Australia</country>; <target id="aff3" target-type="aff"><sup>3</sup></target>Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, <country>Australia</country></aff>
</contrib-group>
<author-notes>
<fn id="afn1">
<p><italic>Contributions:</italic> (I) Conception and design: N Al Hafid; (II) Administrative support: J Christodoulou; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: N Al Hafid; (V) Data analysis and interpretation: N Al Hafid; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p>
</fn>
<corresp id="cor1"><italic>Correspondence to:</italic> Professor John Christodoulou. Western Sydney Genetics Program, Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia. Email: <email xlink:href="john.christodoulou@health.nsw.gov.au">john.christodoulou@health.nsw.gov.au</email>.</corresp>
<fn fn-type="conflict">
<p><italic>Conflicts of Interest:</italic> The authors have no conflicts of interest to declare.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2015</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>10</month>
<year>2015</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>304</fpage>
<lpage>317</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>2015 Translational Pediatrics. All rights reserved.</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>Translational Pediatrics.</copyright-holder>
</permissions>
<abstract>
<p>Phenylketonuria (PKU) is an autosomal recessive inborn error of metabolism caused by a deficiency in the hepatic enzyme phenylalanine hydroxylase (PAH). If left untreated, the main clinical feature is intellectual disability. Treatment, which includes a low Phe diet supplemented with amino acid formulas, commences soon after diagnosis within the first weeks of life. Although dietary treatment has been successful in preventing intellectual disability in early treated PKU patients, there are major issues with dietary compliance due to palatability of the diet. Other potential issues associated with dietary therapy include nutritional deficiencies especially vitamin D and B12. Suboptimal outcomes in cognitive and executive functioning have been reported in patients who adhere poorly to dietary therapy. There have been continuous attempts at improving the quality of medical foods including their palatability. Advances in dietary therapy such as the use of large neutral amino acids (LNAA) and glycomacropeptides (GMP; found within the whey fraction of bovine milk) have been explored. Gene therapy and enzyme replacement or substitution therapy have yielded more promising data in the recent years. In this review the current and possible future treatments for PKU are discussed.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>Phenylketonuria (PKU)</kwd>
<kwd>phenylalanine hydroxylase (PAH)</kwd>
<kwd>dietary therapy</kwd>
<kwd>tetrahydrobiopterin</kwd>
<kwd>large neutral amino acids (LNAA)</kwd>
<kwd>glycomacropeptides (GMP)</kwd>
<kwd>phenylalanine ammonia lyase</kwd>
<kwd>probiotic</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>